Mercury Laboratories Ltd
Incorporated in 1962, Mercury Laboratories
Ltd manufactures and exports Pharmaceutical items of gynec and pediatrics
- Market Cap ₹ 112 Cr.
- Current Price ₹ 932
- High / Low ₹ 1,303 / 760
- Stock P/E 28.0
- Book Value ₹ 431
- Dividend Yield 0.38 %
- ROCE 13.4 %
- ROE 11.6 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
- Company is almost debt free.
Cons
- The company has delivered a poor sales growth of 6.36% over past five years.
- Company has a low return on equity of 11.3% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Formulations
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
33.46 | 41.45 | 41.19 | 47.51 | 48.02 | 51.86 | 55.52 | 57.27 | 68.60 | 57.92 | 75.33 | 75.56 | 69.35 | |
29.63 | 35.08 | 35.40 | 41.04 | 41.30 | 47.44 | 49.79 | 51.10 | 59.01 | 50.92 | 66.73 | 66.53 | 61.54 | |
Operating Profit | 3.83 | 6.37 | 5.79 | 6.47 | 6.72 | 4.42 | 5.73 | 6.17 | 9.59 | 7.00 | 8.60 | 9.03 | 7.81 |
OPM % | 11.45% | 15.37% | 14.06% | 13.62% | 13.99% | 8.52% | 10.32% | 10.77% | 13.98% | 12.09% | 11.42% | 11.95% | 11.26% |
0.72 | 0.79 | 1.12 | 0.78 | 0.35 | 0.42 | 1.04 | 0.85 | 0.88 | 0.94 | 1.69 | 1.09 | 0.95 | |
Interest | 0.41 | 1.47 | 1.12 | 1.13 | 0.89 | 0.91 | 1.09 | 0.82 | 0.64 | 0.45 | 0.36 | 0.38 | 0.49 |
Depreciation | 0.32 | 0.89 | 1.18 | 1.18 | 1.29 | 1.47 | 1.63 | 1.87 | 1.92 | 2.45 | 2.48 | 2.82 | 2.85 |
Profit before tax | 3.82 | 4.80 | 4.61 | 4.94 | 4.89 | 2.46 | 4.05 | 4.33 | 7.91 | 5.04 | 7.45 | 6.92 | 5.42 |
Tax % | 33.51% | 32.71% | 27.98% | 20.45% | 44.79% | 17.89% | 29.88% | 25.40% | 32.49% | 29.17% | 24.97% | 18.35% | |
2.54 | 3.22 | 3.31 | 3.92 | 2.70 | 2.01 | 2.84 | 3.23 | 5.34 | 3.56 | 5.58 | 5.65 | 3.99 | |
EPS in Rs | 21.17 | 26.83 | 27.58 | 32.67 | 22.50 | 16.75 | 23.67 | 26.92 | 44.50 | 29.67 | 46.50 | 47.08 | 33.25 |
Dividend Payout % | 7.09% | 5.59% | 5.44% | 4.59% | 6.67% | 8.96% | 6.34% | 7.43% | 7.87% | 11.80% | 7.53% | 7.43% |
Compounded Sales Growth | |
---|---|
10 Years: | 6% |
5 Years: | 6% |
3 Years: | 3% |
TTM: | -10% |
Compounded Profit Growth | |
---|---|
10 Years: | 6% |
5 Years: | 15% |
3 Years: | 2% |
TTM: | 14% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | 28% |
3 Years: | 13% |
1 Year: | 2% |
Return on Equity | |
---|---|
10 Years: | 12% |
5 Years: | 12% |
3 Years: | 11% |
Last Year: | 12% |
Balance Sheet
Figures in Rs. Crores
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 1.20 | 1.20 | 1.20 | 1.20 | 1.20 | 1.20 | 1.20 | 1.20 | 1.20 | 1.20 | 1.20 | 1.20 | 1.20 |
Reserves | 11.19 | 14.21 | 16.94 | 20.65 | 23.27 | 25.15 | 27.77 | 30.78 | 35.69 | 39.11 | 44.43 | 49.64 | 50.50 |
8.63 | 11.24 | 8.88 | 7.37 | 7.44 | 9.76 | 9.56 | 7.19 | 7.10 | 5.99 | 5.83 | 5.55 | 4.60 | |
11.86 | 13.56 | 15.50 | 17.30 | 19.23 | 15.59 | 18.76 | 17.13 | 21.38 | 16.14 | 12.70 | 11.57 | 13.13 | |
Total Liabilities | 32.88 | 40.21 | 42.52 | 46.52 | 51.14 | 51.70 | 57.29 | 56.30 | 65.37 | 62.44 | 64.16 | 67.96 | 69.43 |
17.89 | 19.48 | 19.48 | 18.57 | 18.39 | 20.78 | 24.39 | 23.66 | 26.36 | 25.82 | 24.26 | 24.03 | 24.92 | |
CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.40 | 0.24 | 0.00 | 0.00 | 0.00 | 0.00 | 0.13 | 3.82 | 7.51 |
Investments | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
14.98 | 20.72 | 23.03 | 27.94 | 32.34 | 30.67 | 32.89 | 32.63 | 39.00 | 36.61 | 39.76 | 40.10 | 36.99 | |
Total Assets | 32.88 | 40.21 | 42.52 | 46.52 | 51.14 | 51.70 | 57.29 | 56.30 | 65.37 | 62.44 | 64.16 | 67.96 | 69.43 |
Cash Flows
Figures in Rs. Crores
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
6.95 | 3.47 | 3.49 | -0.10 | 1.92 | 4.97 | 5.22 | 5.49 | 8.21 | 5.19 | 2.45 | 8.23 | |
-11.63 | -2.48 | -1.54 | -0.28 | -1.50 | -3.68 | -4.99 | -1.14 | -4.62 | -1.89 | -1.06 | -6.27 | |
5.20 | -1.04 | -2.12 | 0.47 | -0.25 | 1.07 | -2.54 | -3.33 | -1.24 | -1.23 | -1.01 | -1.04 | |
Net Cash Flow | 0.52 | -0.05 | -0.18 | 0.09 | 0.17 | 2.36 | -2.31 | 1.02 | 2.36 | 2.07 | 0.38 | 0.91 |
Ratios
Figures in Rs. Crores
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 67.31 | 104.70 | 107.84 | 103.02 | 133.25 | 103.60 | 126.82 | 115.61 | 119.93 | 105.49 | 103.55 | 105.55 |
Inventory Days | 89.52 | 72.20 | 93.92 | 115.50 | 137.30 | 119.80 | 93.95 | 78.44 | 60.42 | 104.59 | 82.82 | 74.81 |
Days Payable | 152.83 | 135.37 | 159.39 | 136.34 | 186.56 | 138.65 | 161.71 | 120.01 | 137.94 | 105.98 | 76.58 | 62.40 |
Cash Conversion Cycle | 4.00 | 41.53 | 42.37 | 82.19 | 83.99 | 84.75 | 59.05 | 74.04 | 42.41 | 104.10 | 109.79 | 117.96 |
Working Capital Days | 29.34 | 33.90 | 44.22 | 75.52 | 102.84 | 90.58 | 88.75 | 88.78 | 75.02 | 98.50 | 103.35 | 102.94 |
ROCE % | 24.64% | 25.68% | 21.35% | 21.59% | 18.91% | 9.82% | 13.77% | 13.26% | 20.56% | 11.83% | 16.04% | 13.41% |
Documents
Announcements
-
Communication To Shareholders-Form DPT-1 Circular Or Circular In The Form Of Advertisement Inviting Unsecured Fixed Deposits From Members
16 Dec - Invitation for unsecured fixed deposits from shareholders.
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
16 Nov - Of Newpaper publication of Unaudited Financial Results for the quarter and half year ended on September 30, 2024
-
Revised Results-For The Quarter And Half Year Ended On September 30, 2024
15 Nov - Revised unaudited financial results for Q2 and H1 2024.
-
Revised Outcome Of The Board Meeting Held On November 14, 2024
15 Nov - Revised unaudited financial results for Q2 and H1 2024.
- Results-For The Quarter And Half Year Ended On September 30, 2024 14 Nov
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2007
from bse
-
Financial Year 2006
from bse
Product Categories:[1]
Analgesic, Anti-inflammatory, Anti-pyretic, Anthelmintic, Antibiotic, Anti-coagulant,
Anti- platelet, Bleeding agents, Anti-fungal, Anti-hypertensive drugs, Anti malarial drugs, Cardiovascular System, Central Nervous System, Eye, Gastro-intestinal system, Hypoglycemic (Anti-diabetic), Multivitamin, Protein supplement, Respiratory System, Anti- allergic, Steroids, Urinary system, Uterine stimulant, Tablets, Oral Liquids, Small Volume Parenterals, Eye/Ear Drops